Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane

Pediatr Blood Cancer. 2023 Oct;70(10):e30604. doi: 10.1002/pbc.30604. Epub 2023 Jul 28.

Authors

Annelies M C Mavinkurve-Groothuis¹, Esmee C de Baat¹, Elizabeth A M Feijen¹, Leontien C M Kremer^{1

2

3}, Saro H Armenian⁴, Renee L Mulder¹, Elvira C van Dalen¹

Affiliations

¹ Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
² Department of Pediatric Cardiology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands.
³ Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
⁴ Population Sciences, City of Hope National Medical Center, Duarte, California, USA.

PMID: 37505793
DOI: 10.1002/pbc.30604

No abstract available

Publication types

Letter
Comment

MeSH terms

Anthracyclines / adverse effects
Antibiotics, Antineoplastic / therapeutic use
Cardiotonic Agents / therapeutic use
Cardiotoxicity / etiology
Cardiotoxicity / prevention & control
Child
Dexrazoxane* / therapeutic use
Humans
Neoplasms* / drug therapy
Polyketides* / therapeutic use
Razoxane* / therapeutic use

Substances

Dexrazoxane
Anthracyclines
Antibiotics, Antineoplastic
Polyketides
Razoxane
Cardiotonic Agents